LAVA Therapeutics (NASDAQ:LVTX) Stock Price Up 5.1% – Should You Buy?

LAVA Therapeutics N.V. (NASDAQ:LVTX) rose 5.1% during mid-day trading on Monday . The company traded as high as $1.57 and last traded at $1.56. Approximately 278,100 shares traded hands during mid-day trading, a decline of 23% from the average daily volume of 359,210 shares. The stock had previously closed at $1.49.

Analyst Ratings Changes

LVTX has been the subject of a number of research analyst reports. HC Wainwright reduced their price target on shares of LAVA Therapeutics from $1.50 to $1.24 and set a “neutral” rating for the company in a research report on Tuesday, August 5th. Jefferies Financial Group lowered shares of LAVA Therapeutics from a “buy” rating to a “hold” rating and reduced their price target for the stock from $3.00 to $1.50 in a research report on Tuesday, August 5th. Six research analysts have rated the stock with a Hold rating, According to data from MarketBeat, LAVA Therapeutics has a consensus rating of “Hold” and a consensus price target of $2.69.

LAVA Therapeutics Price Performance

The firm has a fifty day simple moving average of $1.51 and a 200 day simple moving average of $1.36. The company has a market cap of $41.04 million, a price-to-earnings ratio of -1.49 and a beta of 0.50.

LAVA Therapeutics (NASDAQ:LVTX) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.04). Analysts expect that LAVA Therapeutics N.V. will post -1.13 earnings per share for the current year.

Insider Activity

In other news, major shareholder Versant Venture Capital Vi, L. sold 228,791 shares of the firm’s stock in a transaction on Thursday, September 18th. The shares were sold at an average price of $1.44, for a total value of $329,459.04. Following the sale, the insider owned 532,870 shares in the company, valued at approximately $767,332.80. This trade represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 1,684,434 shares of company stock valued at $2,500,062 in the last 90 days. Company insiders own 9.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BML Capital Management LLC lifted its holdings in shares of LAVA Therapeutics by 0.5% during the second quarter. BML Capital Management LLC now owns 1,970,610 shares of the company’s stock valued at $2,601,000 after acquiring an additional 10,000 shares during the period. BNP Paribas Financial Markets bought a new position in shares of LAVA Therapeutics during the fourth quarter valued at $40,000. Lepercq De Neuflize Asset Management LLC lifted its holdings in shares of LAVA Therapeutics by 34.8% during the second quarter. Lepercq De Neuflize Asset Management LLC now owns 31,000 shares of the company’s stock valued at $41,000 after acquiring an additional 8,000 shares during the period. Rangeley Capital LLC bought a new position in shares of LAVA Therapeutics during the second quarter valued at $36,000. Finally, XTX Topco Ltd bought a new position in shares of LAVA Therapeutics during the first quarter valued at $31,000.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.